הכנסות חזויות של החברה: Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals (MIST) is developing a high-margin tachycardia treatment with minimal production costs. The company is establishing an emergency care system by integrating the drug into patients' daily lives, although it currently faces a liquidity shortage due to launch expenses. The company's projected sales volume exhibits a sideways trend, with the indicator standing at 0.00, highlighting the gap between the share price and its potential.

This indicator measures expected revenue as the basis for market value, allowing investors to assess the gap between the asset's current price and its future scale. The trend in projected sales for Milestone Pharmaceuticals (MIST) reflects the company's critical dependence on its commercial partner while awaiting regulatory drug approval in the absence of M&A transactions.